201 related articles for article (PubMed ID: 38219798)
1. SMART use of medications for the treatment of adolescent severe obesity: A sequential multiple assignment randomized trial protocol.
Fox CK; Vock DM; Sherwood NE; Gross AC; Ryder JR; Bensignor MO; Bomberg EM; Sunni M; Bramante CT; Jacobs N; Raatz SJ; Kelly AS
Contemp Clin Trials; 2024 Mar; 138():107444. PubMed ID: 38219798
[TBL] [Abstract][Full Text] [Related]
2. Combination phentermine and topiramate extended release in the management of obesity.
Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
[TBL] [Abstract][Full Text] [Related]
3. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Kiortsis DN
Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
[TBL] [Abstract][Full Text] [Related]
4. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
5. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
[TBL] [Abstract][Full Text] [Related]
7. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.
Lim F; Bellows BK; Tan SX; Aziz Z; Woo Baidal JA; Kelly AS; Hur C
JAMA Netw Open; 2023 Aug; 6(8):e2329178. PubMed ID: 37651143
[TBL] [Abstract][Full Text] [Related]
9. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.
Mital S; Nguyen HV
JAMA Netw Open; 2023 Oct; 6(10):e2336400. PubMed ID: 37824146
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
Song JE; Ko HJ; Kim AS
Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
[TBL] [Abstract][Full Text] [Related]
13. Current and future pharmacotherapies for obesity in children and adolescents.
Kelly AS
Nat Rev Endocrinol; 2023 Sep; 19(9):534-541. PubMed ID: 37337008
[TBL] [Abstract][Full Text] [Related]
14. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
Allison DB; Gadde KM; Garvey WT; Peterson CA; Schwiers ML; Najarian T; Tam PY; Troupin B; Day WW
Obesity (Silver Spring); 2012 Feb; 20(2):330-42. PubMed ID: 22051941
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
Winslow DH; Bowden CH; DiDonato KP; McCullough PA
Sleep; 2012 Nov; 35(11):1529-39. PubMed ID: 23115402
[TBL] [Abstract][Full Text] [Related]
16. Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
Halpern B; Faria AM; Halpern A
Expert Rev Clin Pharmacol; 2013 May; 6(3):235-41. PubMed ID: 23656337
[TBL] [Abstract][Full Text] [Related]
17. Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
Firkins SA; Chittajallu V; Flora B; Yoo H; Simons-Linares R
Obes Surg; 2024 May; 34(5):1415-1424. PubMed ID: 38512645
[TBL] [Abstract][Full Text] [Related]
18. Phentermine/Topiramate: Pediatric First Approval.
Dhillon S
Paediatr Drugs; 2022 Nov; 24(6):715-720. PubMed ID: 36059008
[TBL] [Abstract][Full Text] [Related]
19. Phentermine and topiramate for the management of obesity: a review.
Cosentino G; Conrad AO; Uwaifo GI
Drug Des Devel Ther; 2013; 7():267-78. PubMed ID: 23630412
[TBL] [Abstract][Full Text] [Related]
20. ACS chemical neuroscience molecule spotlight on Qnexa.
Mercer SL
ACS Chem Neurosci; 2011 Apr; 2(4):183-4. PubMed ID: 22778866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
